Zusammenfassung
Die Entwicklung der Gerontopsychopharmakologie wurde nicht, wie das für die allgemeine Psychopharmakologie der Fall war, durch die zufällige Entdekkung klinisch eindeutig wirksamer Substanzen — wie z. B. des antipsychotisch wirksamen Chlorpromazins im Jahre 1952 durch Delay u. Denniker — eingeleitet. Hinzukommt, daß die systematische wissenschaftliche Untersuchung dieser Substanzen ihrerseits eine auf pharmakologischen Hinweisen beruhende biologische Ursachenforschung der Depression und Schizophrenie induziert hat. Da ähnliche „glückliche“ Entdeckungen bisher der Gerontopsychopharmakologie nicht zuteil wurden, sind in diesem Bereich andere Strategien zur Entwicklung einer rationalen Gerontopharmakotherapie erforderlich. Eine sich anbietende Chance liegt vor allem in der Intensivierung der Erforschung der biochemischen Grundlagen der morphologischen Veränderungen des sog. physiologischen Alterungsprozesses sowie der degenerativ bzw. vaskulär bedingten Abbauerkrankungen. Das Fehlen pharmakologischer Wegweiser im oben genannten Sinne muß dabei durch die auf der Basis der Grundlagenforschung entwikkelten hypothetischen pharmakologischen Modelle ersetzt werden. Wenn auch bisher die Mehrzahl der zu prüfenden hypothetischen pharmakologischen Modelle im Endergebnis nicht bestätigt werden konnten, so liegt ihr Wert trotzdem in der Etablierung einer beginnenden und naturgemäß noch sehr simplifizierenden rationalen gerontopharmakologischen Forschung. Diese Forschungsansätze einer rationalen Gerontopharmakologie sollten in Zukunft stärker gefördert und unterstützt werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abbuzzahab FS, Mervin GE, Zimmermann RC, Sherman MC (1978) A double-blind investigation of piracetam (nootropil) versus placebo in the memory of geriatric inpatients. Psychopharmacol Bull 14: 23–25
Admani AK (1978) New approach to treatment of recent stroke. Brit Med J 2: 1678–1679
Adolfsson R, Gottfries CG, Ross BE, Winblad B (1979) Changes in brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatr 135: 216–223
Adolfsson R, Brane G, Bucht G, Karlsson J, Gottfries CG, Persson S, Winblad B (1982) A double-blind study with levodopa in dementia of Alzheimer type. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Raven, New York, pp 469–473
Amery WK, Wauquier A, van Nueten JM, de Clerk T, van Reempts JV, Janssen PAJ (1981) The anti-migranous pharmacology of flunarizine (R 14 950). A calcium antagonist. Drugs Explt Clin Res 7 (1): 1–10
Angelucci L, Patachhioli FR (1983) Integrative neurohumoral mechanisms relevance to the aging of the brain. In: Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G (eds) Aging of the brain. Aging, Vol 22. Raven, New York, pp 373–380
Arrigo A, Braun P, Kauchtschischwili GM, Moglia A, Tartara A (1973) Influence of treatment on symptomatology and correlated electroencephalographic ( EEG) changes in the aged. Curr Ther Res 15: 417–426
Ashford JW, Soldinger S, Schaeffer J, Cochran L, Jarvik LF (1981) Physostigmine and its effect on six patients with dementia. Am J Psychiatry 138: 829–830
Aurousseau M, Dupont M, Rondeaux JC, Rondeaux C (1972) Variation de l’irrigation sanguine cérébrale sous l’influence de quelques dérivés indoliques apparentes à la vinca-mine. Chim Thér VII: 235–243
Bajada S (1982) A trial of choline chloride and physostigmine in Alzheimer’s dementia. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19. Raven, New York, pp 427–432
Bartus RT (1979) Physostigmine and recent memory: Effects in young and aged nonhuman primates. Science 206: 1087–1089
Bartus RT (1981) Age related memory loss and cholinergic dysfunction: possible directions based on animal models. In: Crook T, Gershon S (eds) Strategies for the development of an effective treatment for senile dementia. Mark Powley, New Canaan, pp 71–89
Bartus RT, Dean RL, Beer B (1980) Memory deficits in aged Cebus monkey and facilitation with central cholinomimetics. Neurobiol Aging I: 145–152
Beneovà O, Pavlik A (1982) Maldevelopment of CNS induced by perinatal metabolic insults and possibilities of its regulations. In: Yoshida H, Hagihara Y, Ebashi S (eds) Advanc. Pharmacol. and Therapeutics II, Vol 5. Pergamon, Oxford New York, pp 195–209
Berlet HA, Ilzenhöfer H (1980) Intracelluläre Bindung von “C-Bencyclan-Hydrogenfumarat im Rattengehirn in vivo. In: Balas P, Kappert A (Hrsg) Folia Angiologica Supplementa, Vol VII. Koska, Berlin Wien, pp 32–41
Bijlsma UG, Funcke ABH, Tersteege M, Rekker RF, Ernsting MJE, Nauta WT (1956) The pharmacology of cyclospasmol. Arch Int Pharmacodyn Ther 105: 145–174
Blake DR, Dodd MJ, Evans JG (1978) Vasopressin in amnesia. Lancet I: 608
Bodie NH (1977) A double blind trial of naftidrofuryl in treating confused elderly patients in general practice. Practitionier 218: 274–278
Böger J (1975) Die cerebrale Insuffizienz im Flimmerverschmelzungstest. Geriatrie 5: 336–342
Bohus B (1982) Neuropeptide und Gedächtnis. In: Bente D, Coper H, Kanowski S (Hrsg) Hirnorganische Psychosyndrome im Alter. Springer, Berlin Heidelberg New York, S 176–186
Bohus B, Kovàcz GL, de Wied D (1978) Oxytocin, vasopressin and memory. Opposite effects on consolidation and retrieval processes. Brain Res 157: 414–417
Bondareff W, Mountjoy CQ, Roth M (1981) Selective loss of neurons of origin of adrenergic projection in cerebral cortex ( Nucleus locus coeruleus) in senile dementia. Lancet I: 783–784
Boniver R (1979) Vertigo particularly of vascular origin, treated with flunarizine. Acta Otorhinolaryngologica (Belg) 33: 270–281
Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99: 459–496
Bowen DM, Benton S, Curzon G, Davison AN, Sims NR, Smith CCT, Spillane JA, White P (1981) Biochemical changes in cortical brain biopsies and cerebrospinal fluid from demented patients including some with Alzheimer’s disease ( AD ). Proc Int Soc Neurochem 8: 339–342
Bowen DM, Sims RN, Benton S, Haan EA, Smith CCT, Neary D, Thomas DJ, Davison AN (1982) Biochemical changes in cortical brain biopsies from demented patients in relation to morphological findings and pathogenesis. In: Corkin S, Davis L, Crowdon HJ, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19. Raven, New York, pp 1–8
Branconnier RJ, Cole JO, Gardos G (1978) ACTH4–10 in the amelioration of neuropsychological symptomatology with senile organic brain syndrome. Psychopharmacol Bull 14: 27–30
Braverman AM, Naylor R (1975) Vasoactive substances in the management of elderly patients suffering from dementia. Modern Geriatric 5: 20–29
Brenner G (1973) Beeinflußbarkeit des ATP-Gehaltes menschlicher und tierischer Erythrocyten in vivo und in vitro durch Xantinolnicotinat. Drug Res 23: 562–566
Brenner G, Brenner H (1972) Die Einwirkung von Xantinol-Nicotinat auf den Stoffwechsel des Gehirns. Drug Res 22: 754–759
Brinkmann SD, Pomara N, Goodnick PJ, Barnett N, Domino EF (1982a) J Clin Psychopharmacol 2: 281–285
Brinkmann SD, Smith RC, Meyer JS, Vronlis G, Shaw K, Gordon JR, Allen RH (1982b) Lecithin and memory training in suspected Alzheimer’s disease. J Gerontol 37: 4–9
Bruckner GW, Jansen W (1979) Zur Therapie der zerebrovasculären Insuffizienz. Minch Med Wschr 121: 861–864
Burnotte RE, Gobert JG, Temmerman JJ (1973) Piracetam-induzierte Veränderungen des Hirnpolyribosomen-Musters bei alternden Ratten. Biochem Pharmac 22: 811–814
Capon A, de Rood M, Verbist A, Fruhling J (1977) Action of vasodilators on regional cerebral blood flow in subacute or chronic cerebral ischemia. Stroke 8: 25–29
Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine F (1981) Piracetam in elderly psychiatric patients. Psychopharmacol Bull 17: 120
Christie JE (1982) Physostigmine and arecoline infusions in Alzheimer’s disease. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Raven, New York. Aging Vol 19:413–419
Christie JE, Shering A, Ferguson J, Glen AJM (1981) Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138: 46–50
Cohen EL and Wurtman RJ (1975) Brain acetylcholine: Increase after systemic choline administration. Life Sci 16: 1095–1102
Cook P and James J (1981a) Cerebral vasodilators, Part I. New Engl J Med 305: 1508–1513
Cook P and James J (1981b) Cerebral vasodilators, Part II. New Engl J Med 305: 1560–1564
Cooper AJ and Magnus RV (1980) A placebo-controlled study of pyritinol (encephabol) in dementia. Pharmatherapeutica 2: 317–322
Creytens G (1980) Nouveautés dans le traitement de la pathologie cérébrale. Acta Therapeutica 6: 33–53
Cross AJ, Crow TJ, Perry RH, Blessed G, Tomlinson BE (1981) Reduced dopamine ß-hydrogenase activity in Alzheimer’s disease. Br Med J 282: 93–94
Dartenuc JY, Belloussot T, Meriaud M, Cavel M, Choussat H (1978) Etude en double-avengle du Praxilène dans l’insuffisance circulatoire cérébrale du vieillard. Geriatrie 6: 325–327
Davies P (1979) Neurotransmitter-related enzymes in senile dementia of Alzheimer type. Brain Res 171: 319–327
Davies P (1980) Open Discussion. In: Cole O, Barett JE (eds) Psychopathology in the Aged. Raven, New York, pp 297–303
Davies P and Maloney JF (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet II: 1403
Davis KL, Mohs RC, Davis BM, Horvath TB, Tinklenberg JR, Rosenberg GS, Levy MJ (1980a) Human memory and the effect of physostigmine and choline chloride. Psychopharmacol Bull 16: 27–28
Davis KL, Mohs RC, Tinklenberg JR, Hollister LE, Pfefferbaum A, Kopell BS (1980b) Cholinomimetics and memory: The effect of choline chloride. Arch Neurol 37: 49–52
De Cree J, De Cook W, Geukens H, De Clerk F, Beerens M, Verhaegen H (1979) The rheological effects of cinnarizine and flunarizine in normal and pathologic conditions. Angiology 30: 505–515
Delay J et Dennicker P (1952) 38 cas des psychoses traitées par la cure prolongée et continuée de 4568 R.P. Ann Méd Psychol 110:364–367
Denecker SJ and Lindberg D (1977) A controlled double-blind study of piracetam in the treatment of senile dementia. Nord Psykiat Tidskr 31: 48–52
Depresseux JC (1978) The effect of vincamine on the regional cerebral blood flow in man. Europ Neurol 17: 100–107
Depresseux JC (1982) Etude de l’action du nicotinate de Xantinol dans l’ischémie cérébrale aiguë. Acta thérapeutica 8: 209–222
Deusinger JM, Haase H (1972) Experimentelle Untersuchungen zur Wirkung von Pyrithioxin auf das Kurzzeitgedächtnis und das unmittelbare Verhalten. Pharmakopsychiat NeuroPsychopharm 6: 283–294
Deutsch JA (1971) The cholinergic synapsis and the site of memory. Science 174: 788–794
Diemiath HE (1966) Hirnstereotaktische Untersuchungen über Pyrithioxin (Encephabol). Klin Med (Wien) 8: 458–462
Dimond SJ and Brouwers EM (1976) Increase in the power of human memory in normal man through the use of drugs. Psychopharmacology 49: 307–309
Dolce G (1970) Neurophysiologische Untersuchungen zur Wirkung von Pyrithioxin auf das zentrale Nervensystem der Katze. Pharmakopsychiat Neuro-Psychopharmak 3: 355–370
Domino EF, Minor L, Duff JF, Tait S, Gershon S (1982) Effects of oral lecithin on blood choline levels and memory tests in geriatric volunteers. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19 Raven, New York, pp 393–397
Domschky K, Nelson M, Dammhayn B, Terjung E (1977) Flunarizin bei Patienten mit zerebraler und peripherer Mangeldurchblutung. Med Welt 28: 1062–1064
Drachmann DA (1977) Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurol 27: 783–790
Drachmann DA (1981) The cholinergic system, memory, and aging. In: Enna T, Samorajski B, Beer B (eds) Aging Vol 17, Raven Press, New York, pp 255–268
Drachmann DA (1983) How normal aging relates to dementia: A critique and classification. In: Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G (eds) Aging of the brain, Aging Vol 22. Raven, New York
Drachmann DA and Laevitt J (1974) Human memory and the cholinergic system: A relationship to aging? Arch Neurol 30: 113–121
Drillisch C, Gierke W (1980) Ergebnisse der Behandlung von Migräne-Patienten mit Cinnarizin und Flunarizin. Med Welt 31: 1870–1872
Duvoisin RC (1975) Antagonism of levodopa by papaverine. JAMA 231: 845–846
Dysken MW, Foval P, Harris CM, Noronha A, Bergen D, Hoepner T, Davis JM (1982) Lecithin administration in patients with primary degenerative dementia and in normal volunteers. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19. Raven, New York, pp 385–392
Eckmann F (1976) Klinische Untersuchungen mit einem Vasotherapeutikum im Doppelblindversuch. Geriatrie 6 (10): 3–14
Eckmann F (1980) Zur Therapie des apoplektischen Insults. Therapiewoche 30: 4737–4744
Eisenberg S, Camp MF, Horn MR (1960) The effect of nylidrin hydrochloride (arlidin) on the cerebral circulation. Am J Med Sci 240: 85–92
Ernst AM (1962) Experiments with 0-methylated product of dopamine on cats. Acta Physio Pharmacol Neurol II: 48–53
Etienne P, Dastoor D, Gauthier S, Ludwick R, Collier B (1982) Lecithin in the treatment of Alzheimer’s disease. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress, Aging Vol 19. Raven, New York
Fauchamps A (1979) Controlled studies with dihydroergotoxine in senile cerebral insufficiency. In: Nandy K (ed) Geriatric psychopharmacology. Elsevier, North Holland
Ferris SH, Sathananthan G, Gershon S, Clark C (1977) Senile dementia: Treatment with deanol. J Am Geriatr Soc 25: 241–244
Ferris SH, Reisberg B, Crook T, Friedman E, Schneck MK, Mir P, Sherman AK, Corwin J et al. (1982) Pharmacologic treatment of senile dementia: Choline, L-dopa, piracetam, and choline plus piracetam. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A report of progress. Aging Vol 19. Raven, New York, pp 475–482
Ferris SH, Reisberg B, Gershon S (1980) Neuropeptide effects on cognition in the elderly. In: Poon E (ed) Aging in the 1980s: Selected contemporary issues in the psychology of aging. Am Psychol Assoc, Washington, pp 212–220
Fisman M (1981) Clinical pharmacology of senile dementia. Prog Neuro-Psychopharmacol 5: 447–457
Földi M, Obal F, Szeghy G (1965) Über die Wirkung von Devincan auf das EEG und das Augenhintergrundbild bei Zerebralsklerotikern. Med Welt 2: 2122–2124
Fovall P, Dysken MW, Lazarus LW, Davis LM, Kahn RL, Jope R, Finkel S, Ratan P (1980) Choline bitartrate treatment of Alzheimer-type dementias. Commun Psychopharmacol 4: 141–145
Friedman E, Sherman KA, Ferris SH, Reisberg B, Bartus RT, Schneck MK (1981) Clinical response to choline plus piracetam in senile dementia. Relation to red-cell choline levels. New Engl J Med 304: 1490–1491
Funcke ABH, van Beek MC, Nijland K (1974) Protective action of cyclandelate in hypoxia. Curr Med Res Opion 2: 37–42
Gaillard AWK and Varey CA (1979) Some effects of an ACTH4–9 analogue (Org 2766) on human performance. Psychol Behav 23: 79–84
Gartner ED (1975) Durchblutung, Sauerstoffdruck und pH des cerebralen Cortex unter Einwirkung von Benzyclan. Arzneim-Forsch 25: 887–891
Gedye JL, Exton-Smith AN, Wedwood A (1972) A method for measuring mental performance in the elderly and its use in a pilot clinical trial of meclofenoxate in organic dementia. Age and Aging 1: 74–80
Gibson EG, Peterson C (1982) Biochemical and behavioral parallels in aging and hypoxia. In: Giacobini E, Filogamo G, Giacobini G (eds) The aging brain: Cellular and molecular mechanisms of aging in the nervous system. Aging Vol 20, Raven, New York, pp 107–122
Gibson EG, Jope R, Blass JP (1975) Decreased synthesis of acetylcholine accompanying impaired oxidation of pyruvic acid in rat brain minces. Biochem J 184: 17–23
Giurgea C (1972) Effet facilitateur du piracetam sur un apprentissage répétif chez le rat. J Pharmacol 3: 17–30
Giurgea C (1973) The “nootropic” approach to the integrative activity of the brain. Condition Reflex 8: 108–115
Giurgea C (1982) The nootropic concept and its prospective implications. Drug Development Res 2: 441–446
Gobert J and Temmerman J (1973) Piracetam-induced increase of the rat brain energetic metabolism and of the polyribosome/ribosome ratio in old rats. IVth Intern Meeting of the Int Soc Neurochem, Tokyo 1973 (Abstract 533)
Gold PW, Ballenger JC, Zis AP, Robertson GL, Post RM, Goodwin FK (1979) A vasopressin hypothesis.of affective illness: Preliminary findings. In: Usdin E, Kopin IJ, Barchas J (eds) Catecholamines: Basic and Clinical Frontiers. Pergamon, New York, p 1176
Goodnick PJ, Gershon S (1983) Chemotherapy of cognitive disorders. In: Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G (eds) Aging of the brain. Aging Vol 22. Raven, New York, pp 349–361
Gottfries CG, Gottfries J, Roos BW (1969) Homovanillic acid and 5-hydroxyindolacetic acid in CSF of patients with senile dementia, presenile dementia and parkinsonism. J Neurochem 16: 1341–1345
Gottstein C (1962) Der Hirnkreislauf unter dem Einfluß vasoaktiver Substanzen. Hutig, Heidelberg
Gottstein U (1974) Behandlung der zerebralen Mangeldurchblutung. Eine kritische Übersicht. Internist 15: 575–587
Grossmann N (1983) Akute cerebrale Ischämie. Munch Med Wschr 125: 323–327
Gustafson L, Risberg J, Johanson M, Fransson M, Maximilian VA (1978) Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia. Psychopharmacol 56: 115–118
Gygax P, Ruf G, Wiernsperger N, Baumann T (1979) Effect of adrenergic blockade on cerebral ischemia. In: Zülch KJ, Kaufmann W, Hossmann KA, Hossmann N (eds) Brain and heart infarct II. Springer, Berlin Heidelberg New York, pp 293–305
Hakkarainen H, Hakamies L (1978) Piracetam in the treatment of postconcussional syndrome. Eur Neurol 17: 50–55
Haller C and Kuschinsky W (1981) Reactivity of pial arteries to K+ and H+ before and after ischemia induced by air embolism. Microcirculation I: 141–159
Hamouz W (1977) The use of pyritinol in patients with moderate to severe organic psychosyndrome. Pharmatherapeutica I: 398–404
Halkovec L, Jitak R, Stutova L (1977) Organisches Psychosyndrom im Alter. Ergebnisse einer klinischen Doppelblindprüfung. Ärztl Praxis 29: 88–105
Heiss WD, Podreka J (1978) Assessment of pharmacologic agents on cerebral blood flow. Eur Neurol 17, Suppl 1: 135–143
Heiss WD, Ilsen HW, Wagner R, Pawlik G, Wienhard K (1983) Remote functional depression of glucose metabolism in stroke and its alteration by activating drugs. In: Heiss WD, Phelps ME (eds) Positron emission tomography of the brain. Springer, Berlin Heidelberg New York, pp 162–168
Herrschaft H (1975a) Die regionale Gehirndurchblutung. Springer, Berlin Heidelberg New York
Herrschaft H (1975b) The efficacy and course of action of vaso-and metabolic-active substances on regional cerebral blood flow in patients with cerebro-vascular insufficiency. In: Harper AM, Jennet WB, Miller JD, Rowan JO (eds) Blood flow and metabolism in the brain. Churchill Livingstone, Edinburgh, pp 1124–1128
Herrschaft H (1976) Gehirndurchblutung und Gehirnstoffwechsel. Thieme, Stuttgart
Herrschaft H (1979) Die Therapie der zerebralen Mangeldurchblutung. Deutsches Ärzteblatt, Ärztliche Mitteilungen 76: 2887–2894
Herrschaft H, Gleim F, Duus P (1974) Die Wirkung von Centrophenoxin auf die regionale Gehirndurchblutung bei Patienten mit zerebrovasculärer Insuffizienz. Dt Med Wschr 99: 1707
Herzfeld U, Christian W, Oswald WD, Ronge J, Wittgen M (1972) Zur Wirkungsanalyse von Hydergin im Langzeitversuch. Eine interdiszplinäre Studie. Med Klin 67: 1118–1125
Heyman A, Logue P, Wilkinson W, Holoway D, Hurwitz B (1982) Lecithin therapy of Alzheimer’s disease: A preliminary report. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19. Raven, New York, pp 373–378
Hirsch MJ and Wurtman RJ (1978) Lecithin consumption elevates acetylcholine concentrations in rat brain and adrenal gland. Science 202: 223–225
Hoedt-Rasmussen K, Skinhoj E, Paulson O, Ewald J, Bjerum JK, Fahrenkrug A, Lassen NA (1967) Regional cerebral blood flow in acute apoplexy. Arch Neurol 17: 271–281
Hörmann M (1973) Beitrag zur medikamentösen Therapie aphasischer Störungen nach Hirntraumen und cerebralen Gefäßprozessen. Fortschr d Med 91: 125–130
Hofferberth B (1980) Die Anwendung von Flunarizin bei Patienten mit vertebrobasilärer Insuffizienz. Drug Res 30: 1817
Holtzman E (1976) Lysosomes: A survey (Cell Biology Monographs, Vol 3 ). Springer, Berlin Heidelberg New York
Hotovy R (1977) Arzneim-Forsch 14: 26
Hoyer S (1976) Zur Wirkung von Centrophenoxin auf Durchblutung und oxydativen Stoffwechsel des Gehirns beim organischen Psychosyndrom. Vortrag auf dem CentrophenoxinSymposium, Timmendorfer Strand
Hoyer S (1978) Blood flow and oxidative metabolism of the brain in different phases of dementia. In Katzman R, Terry RD, Bick KL (eds) Alzheimer’s disease: Senile dementia and related disorders. Aging Vol 7. Raven, New York, pp 219–226
Hoyer S (1981) Bei praeseniler oder seniler Demenz: Rechtzeitig das richtige Medikament. Mk Ärztl Fortb 31: 552–554
Hoyer S (1982) Durchblutung und Stoffwechsel des Gehirns bei zerebralen Erkrankungen im mittleren und höheren Lebensalter. Z Gerontol 15: 306–313
Hoyer S, Oesterreich K, Stoll KD (1977) Effects of pyritinol-HC1 on blood flow and oxidative metabolism of the brain in patients with dementia. Arzneim-Forsch 27: 671–674
Hughes RJ, Williams JG, Currier RD (1976) An ergot preparation (hydergine) in the treatment of dementia. Review of clinical literature. J Am Geriatr Soc 14: 490–497
Hutten H, Vaupel P (1975) Der Einfluß von Bencyclan auf den cerebralen Gefäßwiderstand bei normalem und gestörtem Säure-Basen-Status. Med Welt 28: 1567–1572
Hyams DE (1978) Cerebral function and drug therapy. In: Brocklehurst JC (ed) Textbook of geriatric medicine and gerontology, 2nd edn. Churchill Livingstone, Edinburgh, pp 670–711
Iwangoff P, Reichlmeier K, Enz A, Meier-Ruge W (1979) Neurochemical findings in physiological aging of the brain. Interdiscipl Topics Geront 15: 13–33
Iwangoff P, Armbruster R, Enz A, Meier-Ruge W, Sandoz P (1980) Glycolytic enzymes from human autoptic brain cortex: Normally aged and demented cases. In: Roberts PJ (ed) Biochemistry of dementia. Wiley & Sons, England, pp 258–262
Jäger W, Scharrer J, Satkowski U, Breddin K (1975) Thrombocytenaggregationshemmende Wirkung von Bencyclan in vitro und in vivo. Arzneim-Forsch 25: 1938–1944
Jellinger K, Flament H, Henauer S, Dubuis R (1982) Abstracts, 13th CINP Congress, Jerusalem
Jenkins JS, Mather HM, Caughlen AD, Jenkins DG (1979) Desmopressin in post-traumatic amnesia. Lancet I: 1245–1246
Kanig K (1973) Encephalotropic drugs and cerebral RNA metabolism. In: Zippel HP (ed) Memory and transfer of information. Plenum, New York, pp 571–582
Kanig K, Nitschki J, Peiler-Ischikama K (1976) Der Einfluß von Naftidrofuryl auf den 32-PiEinbau in Nukleinsäuren und Adenosinphosphate des Rattengehirns. Drug Res 26: 1209–1212
Kartin P, Povse M, Skondia V (1979) Clinical study of piracetam in patients with subacute cerebrovascular accidents. Acta Therapeutica 5: 235–243
Kaye WH, Weingartner H, Gold P, Ebert MH, Gillin JC, Sitaram N, Smallberg S (1982) Cognitive effects of cholinergic and vasopressor-like agents in patients with primary degenerative dementia. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19. Raven, New York, pp 433–442
Kohlmeyer K (1972) Der Einfluß eines neuen Vasodilatators (Bencyclan) auf die allgemeine und regionale Hirndurchblutung. Herz-Kreislauf 4: 196–203
Kretschmar JA and Kretschmar Ch (1976) Zur Dosis-Wirkungs-Relation bei der Behandlung von Piracetam. Arzneim-Forsch 26: 1158–1159
Kseizak HJ u. Gibson GE (1981) J Neurochem 37: 307–315
Kunkel H and Westphal M (1970) Quantitative EEG analysis of pyrithioxine action. Pharmakopsychiat Neuro-psychopharmakol 3: 41–49
Kugler J, Oswald WD, Herzfeld V, Sens R, Pingel J, Wetzel D (1978) Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dt med Wschr 103: 456–462
Kuschinsky W (1983) Coupling between functional activity, metabolism, and blood flow in the brain: State of the art. Microcirculation 2 (4): 357–378
Kuschinsky W and Wahl M (1978) Local chemical and neurogenic regulations of cerebral vascular resistance. Physiol Rev 57: 656–689
Lagergren K and Levanders S (1977) A double-blind study on the effects of piracetam upon perceptual and psychomotor performance of varied heart rates in patients treated with artificial pacemakers. Psychopharmacology 39: 97–104
Landfield PW, Waymire JC, Lynch G (1978) Hippocampal aging and adrenocorticoids: Quantitative correlations. Science 202: 1089–1102
Lartique-Mattei C, d’Athis P, Lhoste F, Tillement JP (1978) Etude de la pharmacocinétique du naftidrofuryl et de sa biodisponibilité sous forme de gelule chez l’homme. Int J Clin Pharmacol Biopharm 16: 536–539
Le Boeuf A, Lodge J, Eames PG (1978) Vasopressin and memory in Korsakoffs syndrome. Lancet II: 1370
Legros JJ, Gilot P, Seron X, Claessens J, Adam A, Moeglen JM, Audibert A, Berchier P (1978) Influence of vasopressin on learning and memory. Lancet I: 41–43
Lieberman A, Dziatolowski H, Kupersmith M, Serby M, Goodgold A, Korein J, Goldstein M (1979) Dementia in Parkinson disease. Am Neurol 6: 355–359
Loeffelholz K, Lindmar R, Weide W (1978) The relationship between choline and acetylcholine release in the autonomic nervous system. In: Barbeau A, Growdon JH, Wurtman RJ (eds) Choline and lecithin in brain disorders. Raven, New York, pp 223–241
Loew DM (1980) Die Wirkung von Mutterkorn-Derivaten auf das Zentralnervensystem: Synaptische Übertragungsmechanismen. In: Platt P (Hrsg) Funktionsstörungen des Gehirns im Alter. Schattauer, Stuttgart New York, S 83–101
Loew DM (1981) Pharmacological approaches to gerontopsychiatry. In: Hoffmeister F, Stille G (eds) Psychotropic agents II. Handbook of Experimental Pharmacology, Vol 52. Springer, Berlin Heidelberg New York, pp 435–459
Loew DM and Weil C (1982) Hydergine in senile mental impairment. Gerontology 28: 54–74
Loew DM, Vigouret JM, Jaton A (1979) Neuropharmacology of bromocripine and dihydroergotoxine (Hydergine®). In: Goldstein M, Calne DB, Liebermann A, Thorner MO (eds) Ergot compound and brain function, neuroendocrine and neuropsychiatric aspects. Advances Biochem Psychopharm. Vol 23. Raven, New York
Manley ES, Lawson JW (1968) Effect of ß-adrenergic receptor blockade on skeletal muscle vasodilation produced by isoxsuprine and nylidrin. Arch Int Pharmacodyn Ther 175: 239–250
Mann DMA and Sinclair KGA (1978) The quantitative assessment of lipofuscin pigment, cytoplasmic ENA, and nuclear volume in senile dementia. Neuropathol Appl Neurobiol 4: 129–135
Mann DMA and Yates PO (1982) Is the loss of cerebral cortical CAT activity in Alzheimer’s disease due to degeneration of ascending cholinergic cells? J Neurol Neurosurg Psychiatry 45: 936–941
Mann DM and Yates PO (1983) Serotonin nerve cell in Alzheimer’s disease. J Neurol Neurosurg Psychiat 46: 96–98
Mann PJG, Tennenbaum M, Quastel JH (1939) Acetylcholine metabolism in the central nervous system. Biochem J 33: 822–835
Mann DMA, Lincoln J, Yates PO, Stamp JF, Toper S (1980) Changes in the monoamine containing neurons of the human CNS in senile dementia. Br J Psychiatry 136: 533–541
Matejcek M, Knor K, Piquet PV, Weil C (1979) Electroencephalographic and clinical changes as correlated in geriatric patients treated three month with an ergot alkaloid preparation. J Am Geriat Soc 27: 198–202
McFarland RA (1963) Experimental evidence of the relationship between ageing and oxygen want: In search of the theory of ageing. Ergonomics 6: 340–366
McFarland RA, Warren AB, Ravis C (1958) Alterations in critical flicker frequency as a function of age and light/dark ratio. J Exp Psychol 56: 529–538
McGeer E, McGeer PL (1976) Neurotransmitter metabolism in the aging. In: Terry RD, Gershon S (eds) Neurobiology of aging. Aging Vol 3. Raven, New York, pp 383–403
McGeer E, McGeer PL (1980) Aging and neurotransmitter system. In: Goldstein M, Calne DB, Liebermann A, Thorner MO (eds) Ergot compounds and brain function. Series: Adv Biochem Psychopharm Vol 23. Raven, New York
McHenry LC, Jaffe ME, Kawamura J, Goldberg HJ (1970) Effect of papaverin on regional blood flow in focal vascular disease of the brain. N Engl J Med 282: 1167–1170
Meier-Ruge W (1980) Über experimentelle Grundlagen zum Studium von Hirnfunktionsstörungen im Alter. In: Platt D (Hrsg) Funktionsstörungen des Gehirns im Alter. Schattauer, Stuttgart New York, S 31–52
Meyer JP and Catoire JP (1975) Cerebrovascular disorders of ischemic origin. A comparative clinical trial. Lyon méd 234: 801–802
Meyer JS, Gotoh F, Gilroy J, Nara N (1965) Improvement in brain oxygenation and clinical improvement in patients with strokes treated with papaverin hydrochloride. JAMA 194: 957–961
Meyer JS, Kanda T, Shinohara Y et al. (1971) Effect of hexobendine on cerebral hemispheric blood flow and metabolism: Preliminary clinical observations concerning its use in ischemic cerebrovascular disease. Neurology (Minneap) 21: 691–702
Meynaud A, Grand M, Fontaine L (1973) Effect of naftidrofuryl upon energy metabolism of the brain. Drug Res 23: 1431–1436
Millington WR, McCall AC, Wurtman RJ (1978) Deanol acetamidobenzoate inhibits the blood brain barrier transport of choline. Ann Neurol 4: 302–306
Mindus P, Cronheim B, Levander SE, Schalling D (1976) Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. Acta psychiat Scand 54: 150–160
Mongeau B (1974) The effect of hydergine on the transit time of cerebral circulation in diffuse cerebral insufficiency. Europ J Clin Pharmacol 7: 169–175
Nandy K (1968) Further study on the effects of centrophenoxine on the lipofuscin pigment in the neurons of senile guinea pigs. J Gerontol 23: 82–85
Nandy K (1978) Centrophenoxine: Effects on aging mammalian brain. J Am Geriatr Soc 26: 74–81
Nandy K and Bourne GH (1966) Effect of centrophenoxine on the lipofuscin pigment in the neurons of senile guinea pigs. Nature 210: 313–314
Nemoto EM, Snyder JV, Carol! RG, Morita H (1975) Global ischemia in dogs: Cerebrovascular CO, reactivity and autoregulation. Stroke 6: 425–431
Nickel J, Breyer V, Quadbeck G (1963) Research on the effects of centrophenoxine on the CNS. Presented at the International Congress on Selective Psychostimulantia, Roma
Nickolson VJ and Wolthuis OL (1976) Effect of acquisition enhancing drug, piracetam, on rat cerebral energy metabolism. Comparison with naftidrofuryl and metamphetamine. Biochem Pharmacol 25: 2241–2244
Novis SP, Bertoni E, Tosman MH (1980) Doppelblindstudie über die Wirkung von Bencyclan bei Patienten mit cerebrovasculärer Insuffizienz. In: Balas P, Kappert A (Hrsg) Folia Angiologica Supplement, Vol VII. Koska, Berlin Wien, S 110–119
O’Brien MD and Veall N (1966) Effect of cyclandelate on cerebral cortex perfusion-rates in cerebro-vascular disease. Lancet II: 729–730
Oleson J and Paulson OB (1971) The effect of intra-arterial papaverine on the regional cerebral blood flow in patients with stroke or intracranial tumor. Stroke 2: 148–159
Oliveros JC, Jandall MK, Timsit-Berthier M, Remy R, Benghezal A, Audibert A, Moeglen JM (1978) Vasopressin in amnesia. Lancet I: 42
Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977a) Neurotransmitter enzyme, abnormalities in senile dementia. J Neurol Sci 34: 247–265
Perry EK, Perry RH, Blessed G, Tomlinson BE (1977b) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet I: 189
Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PA, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Brit Med J:1457–1459
Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH (1980) Coenzyme A acetylating enzymes in Alzheimer’s disease: Possible cholinergic “compartment” of pyruvate dehydrogenase. Neurosci Lett 18: 105–110
Perry EK, Tomlinson BE, Blessed G, Perry RH, Cross Ai, Crow TJ (1981) Neuropathological and biochemical observations on the noradrenergic system in Alzheimer’s disease. J Neurol Sci 51: 279–287
Peters BH and Levin HS (1982) Chronic oral physostigmine and lecithin administration in memory disorders of aging. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress, Aging Vol 19. Raven, New York, pp 421–426
Pigache RM and Rigter H (1981) Effects of peptides related to ACTH on mood and vigilance in man. In: von Wimersma Greidanus TB (ed) Frontiers of hormone research, Vol 8. Karger, Basel, pp 193–207
Plotkine M. Rousseau B, Bonlu RG (1980) Cortical oxygen availability and electrocorticographic changes in rats submitted to transient cerebral ischemia. In: Betz E, Grote J, Heuser D, Wüllenweber R (eds) Pathophysiology and pharmacotherapy of cerebro-vascular disorders. Witzstrock, Baden-Baden, pp 274–276
Le Poncin-Lafitte M, Boismare F, Saligaut C, Moore N (1981) Effets de l’hypoxie hypobare sur le conditionnement et les faux cérébraux d’ADP, d’AMP, de dopamine et de noradrenaline chez le rat traité ou non par le naftidrofuryl. J Pharmacol (Paris) 12: 51–57
Pope A, Hess HA, Lewin E (1965) Microchemical pathology of the cerebral cortex in pre-senile dementia. Trans Amer Neurol Assoc 89: 15–16
Price DL, Whitehouse PJ, Struble RG, Coyle JT, Clark AW, Delong MR, Cork LC, Hedreen JC (1982) Alzheimer’s Disease and Down’s Syndrome. In: Sinex FM, Merril CR (eds) Alzheimer’s Disease, Down’s Syndrome and Aging. Ann of the NY Acad of Scien, Vol 396
Quadbeck H, Lehmann E (1978) Die Veränderung des oxidativen Glucosestoffwechsels des Gehirns unter langfristiger Xantinol-nikotinat-Medikation. Drug Res 28: 1531–1532
Quadbeck G, Landmann HR, Sachsse W, Schmidt J (1962) Der Einfluß von Pyrithioxin auf die Blut-Hirnschranke. Med exp 7: 144–154
Quadbeck G, Claver B, Minel G (1964) Einfluß von Stimulantien und Antidepressiva auf das Höhen-EEG der Ratte. Arzneim-Forsch 14: 563–567
Reisberg B (1981) Empirical studies in senile dementia with metabolic enhancers and agents that alter blood flow and oxygen utilisation. In: Crook T, Gershon G (eds) Strategies for the development of an effective treatment for senile dementia. Powley, New Canaan, pp 189–206
Reisberg B, Ferris SH, Gershon S (1980) Pharmacotherapy of senile dementia. In: Cole JO, Barett E (eds) Psychopathology in the aged. Raven, New York, pp 233–261
Reisine TD, Yamamura HJ, Bird ED et al. (1978) Pre-and postsynaptic neurochemical alterations in Alzheimer’s disease. Brain Res 159: 477–481
Richardson AE and Bereen FJ (1976) Effect of piracetam on level of consciousness after neurosurgery. Lancet II: 1110–1111
Righter H and Crabbe JC (1979) Modulation of memory by pituitary hormones and related peptides. Vitam Horm 37: 153–241
Rossignol P, Boule R, Ribaot M, Paultré C, Badu S, Tonelle B (1972) Pharmacodynamie — Action de quelques médicaments de l’insuffisance vasculaire cérébrale sur les potentiels poimaires somestésiques voqués au niveau du cortex et du thalamus chez le chat en état d’ischémie cérébrale aiguë. Acad Sci (Paris) 274: 3027–3029
Rossor M, Fahrenkrug J, Emson P, Mountjoy S, Iversen L, Roth M (1980) Reduced cortical choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide. Brain Res, 201: 249–253
Rossor MN, Emson PC, Iverson LL, Mountjoy CQ, Roth M, Fahrenkrug J, Rehfeld JF (1982) Neuropeptides and neurotransmitter in cerebral cortex in Alzheimer’s disease. In: Corkin S, Davis KL, Growdon HJ, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19, Raven, New York, pp 15–24
Sandmann CA, Walker B, Lawton C (1980) An analog of MSH/ACTH4_9 enhances interpersonal and environmental awareness in the mentally retarded. Peptides 1: 109–114
Scheibel AB (1979) The hippocampus: Organizational patterns in health and senescence. Mech Ageing Dev 9: 89–102
Schmid-Schönbein H, Weiss J, Brandhuber M (1975) Der Einfluß von Bencyclan auf das Fließverhalten von Erythrocyten and Vollblut. Herz-Kreislauf 7 (9): 475–480
Seidel G and Endel W (1977) Effect of xantinol-nicotinate-treatment on platelet aggregation. Int J Clin Pharmacol 15: 139–143
Serbi M, Corwin J, Rotrosen J, Ferris SH, Reisberg B, Friedman E, Sherman KA, Jordan B et al. (1983) Lecithin and piracetam in Alzheimer’s disease. Psychopharmacol Bull 19: 126–129
Sierra G and Reinoso-Suarez F (1963) The influence of pyridoxin-disulphide on the electroencephalogramm of free unanaesthetized cats. Med exp (Basel) 84–92
Sitaram N, Weingartner H, Caine ED, Gillin JC (1978a) Choline: Selective enhancement of serial learning and encoding of low imagery words in man. Life Sci 22: 1555–1560
Sitaram N, Weingartner H, Gillin JC (1978b) Human serial learning: Enhancement with arecoline and impairment with scopolamine. Science 201: 274–276
Smith CM, Semple SA, Swash M (1982) Effects of physostigmine on responses in memory tests in patients with Alzheimer’s disease. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19. Raven, New York, pp 405–411
Sofroniew MV and Weindl A (1978) Projection from the parvocellular vasopressin and neurophysin-containing neurons of the suprachiasmatic nucleus. Am J Anat 153: 361–366
Sorbi S, Amaducci L, Blass JP, Bird ED (1982) Pyruvate-5-dehydrogenase complex and choline-acetyltransferase in aging and dementia. In: Giacobini E, Filogamo G, Giacobini G (eds) The aging brain: Cellular and molecular mechanisms of aging in the nervous system. Aging Vol 20. Raven, New York, pp 153–160
Stegink AJ (1972) The clinical use of piracetam. Arzneim-Forsch 22: 975–977
Stoica E, Meyer JS, Kawamura Y, Hiromoto H, Haslik K, Pascu I (1973) Central neurogenic control of cerebral circulation. Neurology 23: 687–697
Sulkin NM (1958) The occurrence and duration of senile pigments experimentally induced in the nerve cells of young rats. Anat Res 130: 377–378
Sullivan EV, Shedlack KJ, Corkin S, Growdon JH (1982) Physostigmine and lecithin in Alzheimer’s disease. In: Corkin S, Davis KL, Growdon E, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19. Raven, New York, pp 361–367
Symon L, Braunston NM, Strong AJ (1976) Autoregulation in acute focal ischemia: An experimental study. Stroke 7: 547–554
Szporny L (1977) Pharmacology of vincamine and its derivatives. Actual Pharmacol (Paris) 23: 87–117
Szporny L and Szasz K (1959) Die pharmakologischen Untersuchungen des Vincamins. Arch exp Path Pharmak 236: 296–298
Tazaki Y, Omae T, Kuromaru S, Ohtomo E, Hasegawa K, Mori A, Kurihara M, Kutsusawa N et al. (1980) Clinical effect of encephabol (pyritinol) in the treatment of cerebrovascular disorders. J Int Med Res 8: 118–126
Terry RD and Davies P (1982) Some morphologic and biochemical aspects of Alzheimer’s disease. In: Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G (eds) Aging of the Brain. Aging Vol 22. Raven, New York, pp 47–59
Tesseris J, Roggen G, Caracalos A, Triandafillov D (1975) Effects of vincamin on cerebral metabolism. Europ Neurol 13: 195–202
Thal L, Rosen W, Sharpless NS, Crystal H (1981) Choline chlorid fails to improve cognition in Alzheimer’s disease. Neurobiol Aging 2: 205–208
Tinklenberg JR, Pigache R, Pfefferbaum A, Berger PA (1982) Vasopressin peptides and dementia. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s disease: A report of progress. Aging Vol 19. Raven, New York, pp 463–467
Tomlinson BE (1977) The pathology of dementia. In: Wells CE (ed) Dementia. Davis, Philadelphia, pp 113–153
Tomlinson BE, Blessed G, Roth M (1968) Observations on the brains of non-demented old people. J Neurol Sci 7: 331–356
Tomlinson BE, Blessed G, Roth M (1970) Observations on the brains of demented old people. J Neurol Sci 11: 205–242
Tonelli M, Ferretti PG, Bonifazi C (1974) Results with vincamine in the management of 45 cases of cerebral vasculopathy in aged subjects. ( Italian ). Gazz med ital 133: 146–157
Ulus IH, Hirsch MJ, Wurtman RJ (1977) Transsynaptic induction of adrenomedullary tyrosine hydroxylase activity by choline: Evidence that choline administration increases cholinergic transmission. Proc Nat Acad Sci USA 74: 789–800
van Nueten JM and Wollens D (1979) Mechanism of vasodilation and antivasoconstriction. Angiology 30: 440–446
Van Nueten JM, van Beek J, Janssen PAJ (1978) Effect of flunarizine on calcium-induced response of peripheral vascular smooth muscle. Arch Int Pharmacodym 232: 42–52
Vehrschild T, Beier R, Friemert K (1975) Langzeitbehandlung der Hirnleistungsschwäche in der Involution mit Cerntil: Ein Doppelblindversuch. Dt Gesundh Wesen 30: 280–282
Venn RD (1980) Review of clinical studies with ergots in gerontology. In: Goldstein M, Calne RB, Liebermann A, Thorner MO (eds) Ergot compounds and brain function. Raven, New York, pp 363–377
Versteeg DHG, de Kloet ER, van Wimersma Greidanus TB, de Wied D (1979) Vasopressin modulates the activity of catecholamine containing neurons in specific brain regions. Neurosci Lett II: 69–73
van Vlasselaer G and Vanhulle G (1980) Doppelblind-Studie mit Bencyclan versus Placebo bei älteren Patienten mit Symptomen von cerebrovasculärer Insuffizienz. Klinische Auswertung und psychometrische Tests. In: Balas P, Kappert A (Hrsg) Folia Angiologica Supplement, Vol VII. Koska, Berlin Wien, pp 103–109
Walter R, Hoffman PL, Flexner JB, Flexner LB (1975) Neurohypophyseal hormones, analogs, and fragments. Their effect on puromycin-induced amnesia. Proc Nat Acad Sci USA 72: 4180–4184
Weber G, Kreisel T, Peter S, Künzel J (1980) A double blind placebo controlled cross-over study in patients with peripheral vascular diseases, using a new capillary viscometer. Angiology 31: 1–5
Weil C (1980) In: Berde B, Schild HO (Hrsg) Pharmakologie und klinische Pharmakologie von Hydergin®. Springer, Berlin Heidelberg New York, pp 34–36
Weingartner H, Gold P, Ballenger JC, Smallberg SA, Summers R, Rubinow DR, Post RM, Goodwin FK (1981) Effect of vasopressin on human memory function. Science 211: 601–603
Westreich G, Alter M, Lundgren S (1975) Effect of cyclandelate on dementia. Stroke 6: 535–538
White BC, Gadzinski DS, Hoehner PJ, Krome C, Hoehner T, White JD, Trombley JH (1982) Effect of flumarizine on canine cerebral cortical blood flow and vascular resistance post cardiac arrest. Ann Emergency Med 11: 119–126
White P, Hiley C, Goodhardt M, Carasco LH, Keet JP, Williams JEJ, Bowen DM (1977) Neo-cortical cholinergic neurons in elderly people. Lancet I: 668–670
Whitehouse PJ, Price DL, Clark AW, Coyle JT, Delong MR (1981) Alzheimer’s disease: Evidence for selective loss of cholinergic neurons in the Nucleus basalis. Ann Neurol 10: 122–126
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, de Long MR (1982) Alzheimer’s disease and senile dementia: Loss of neurons in the basal forebrain. Science 215: 1237–1239
de Wied D (1971) Long term effect of vasopressin on the maintenance of a conditioned avoidance response in rats. Nature 232: 58–60
de Wied D (1977) Peptides and behaviour. Life Sci 20: 194–204
Wiernsperger N, Gygax P, Danzeisen M (1978) Cortical pO2 distribution during oligemic hypotension and its pharmacological modifications. Arzneim-Forsch 28: 768–770
von Wild K, Dolce G (1976) Pathophysiological aspects concerning the treatment of the apallic syndrome. J Neurol 213: 143
Witzmann KH and Blechacz W (1977) On the role of vincamine in the therapy of cerebrovascular diseases and impairment of cerebral function. Arzneim-Forsch 27: 1238–1247
Woelk H (1979) Effects of Piracetam on the incorporation of 32P into the phospholipids of neurons and glial cells isolated from rabbit cerebral cortex. Pharmacopsychiat 12: 251–256
Wurtman RI (1983) Choline availability and acetylcholine synthesis: relation to Alzheimer’s disease. In: Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G (eds) Aging of the brain. Aging Vol 22. Raven, New York, pp 211–220
Yamaguchi F, Meyer JS, Yamamoto M, Sakai F, Shaw T (1980) Non-invasive regional cerebral blood flow measures in dementia. Arch Neurol 37: 410–418
Yates CM, Allison Y, Simpson J, Maloney AJF, Gordon A (1979) Dopamine in Alzheimer’s disease and senile dementia. Lancet II: 851–852
Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA (1979) Vasodilators in senile dementia. Arch Gen Psychiatry 36: 220–223
Yoshida K, Ishijima Y, Matsuda M (1968) Effect of cyclandelate on regional cerebral blood flow measured by mitracarotid injection of Xe133 Arch Jpn Chir (Kyoto) 37: 842–853
Zahniser NR, Chou D, Hanin I (1977) Is 2-dimethylamino-ethanol (deanol) indeed a precursor of brain acetylcholine? J Pharmacol Exp Ther 200: 545–548
Zimmer R, Teelken AW, Trieling WB, Weber B, Weihmayr T, Lauter H (1984) γ-aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer’s type. Arch Neurol 41:602–604
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Zimmer, R., Lauter, H. (1986). Neuere pharmakologische Modelle und Forschungsergebnisse in der Therapie der degenerativ und/oder vaskulär bedingten hirnorganischen Psychosyndrome bzw. Demenzen im mittleren und höheren Lebensalter. In: Lauter, H., Möller, HJ., Zimmer, R. (eds) Untersuchungs- und Behandlungsverfahren in der Gerontopsychiatrie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82733-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-82733-4_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-16289-6
Online ISBN: 978-3-642-82733-4
eBook Packages: Springer Book Archive